These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 12613015

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS, Pacificar JS, Shapiro CE, Williams SG.
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
    Mazzei T, Mini E, Eandi M, Reali EF, Fioretto L, Bartoletti R, Rizzo M, Calabrò G, Periti P.
    Drugs Exp Clin Res; 1989 Jun; 15(8):373-87. PubMed ID: 2513176
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
    Cox MC, Scripture CD, Figg WD.
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
    [Abstract] [Full Text] [Related]

  • 14. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH.
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [Abstract] [Full Text] [Related]

  • 15. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
    Fuse H, Akimoto S, Akakura K, Shimazaki J, Murakami S.
    Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
    [Abstract] [Full Text] [Related]

  • 16. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y, Yonese J, Kawakami S, Yamamoto S, Okubo Y, Fukui I.
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [Abstract] [Full Text] [Related]

  • 17. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Kaku H, Saika T, Tsushima T, Ebara S, Senoh T, Yamato T, Nasu Y, Kumon H.
    Prostate; 2006 Mar 01; 66(4):439-44. PubMed ID: 16329145
    [Abstract] [Full Text] [Related]

  • 18. Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals.
    Greil S, Robinson EA, Singal B, Kleer E.
    Urology; 2009 Mar 01; 73(3):631-4. PubMed ID: 19110301
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
    Ohuchi H, Noguchi K, Kinoshita Y, Hosaka M, Kawasaki C, Miura T, Kondo I, Harada M.
    Hinyokika Kiyo; 2000 Aug 01; 46(8):531-6. PubMed ID: 11019371
    [Abstract] [Full Text] [Related]

  • 20. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
    Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventós CX, Catalán R, Reventós J.
    Urol Int; 2006 Aug 01; 77(2):135-8. PubMed ID: 16888418
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.